This compound is primarily investigated for its potential therapeutic applications in treating metabolic disorders, particularly those related to lipid metabolism. It functions as a DGAT2 inhibitor, targeting the enzyme diacylglycerol O-acyltransferase 2, which plays a key role in triglyceride synthesis. By inhibiting DGAT2, it may help reduce excessive fat accumulation in the liver, making it a promising candidate for addressing conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Research is ongoing to explore its efficacy and safety in clinical settings, with the aim of developing novel treatments for metabolic and liver-related diseases.